Document is current
Any future updates will be listed below
-
Authors
Smets, Ide https://orcid.org/0000-0001-8174-2898
Goris, An https://orcid.org/0000-0002-1276-6682
Vandebergh, Marijne https://orcid.org/0000-0001-9645-2615
Demeestere, Jelle https://orcid.org/0000-0001-8186-0237
Sunaert, Stefan https://orcid.org/0000-0002-1177-4680
Dupont, Patrick https://orcid.org/0000-0003-1980-2540
Dubois, Bénédicte https://orcid.org/0000-0003-0604-8702
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G073415N)
KU Leuven (C24/16/045)
Belgian Charcot Foundation
European Committee for Treatment and Research in Multiple Sclerosis (Clinical Fellowship Grant)
MS Liga Vlaanderen
Queen Elisabeth Medical Foundation
- License Information
-
More Information
Article History
Received: 15 September 2020
Accepted: 23 December 2020
First Online: 15 January 2021
Competing interests
: BD has received consulting fees and/or funding from Biogen Idec, Merck, Sanofi, Roche, Novartis and TEVA Pharma Nederland. AG has received consulting/travel fees and/or research funding from Novartis, Roche and Merck. IS, MV, JD, SS and PD have nothing to disclose.
